See today's BioWorld
To read the full story, subscribe or sign in.

Altimmune acquires Velocity's Spitfire and its NASH candidate

July 10, 2019
By Lee Landenberger
Altimmune Inc. will acquire Spitfire Pharma Inc. and its lead candidate, SP-1373 (to be renamed ALT-801), a GLP-1/glucagon receptor co-agonist for treating nonalcoholic steatohepatitis (NASH).
BioWorld Deals and M&A Acquisition Gastrointestinal